Paul John Balson’s ARK Genomic Revolution ETF ARKG Stock Holding History

Paul John Balson’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$1.18M	Buy	12,628 +4,308	+52%	+$343K	0.24%	32
2020 Q3	$530K	Buy	8,320 +1,220	+17%	+$71.5K	0.13%	45
2020 Q2	$370K	Buy	+7,100	New	+$305K	0.14%	53

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

MCM

Mainstay Capital Management Grand Blanc, Michigan $1.3B AUM 37.8% 1-Year Est. Return

CAN

Claraphi Advisory Network Aliso Viejo, United States $251M AUM 9.29% 1-Year Est. Return

Paul John Balson's ARKG Position: Q4 2020 in Review

Paul John Balson increased its ARK Genomic Revolution ETF (ARKG) stake by 52% in Q4 2020, buying an estimated $343K and bringing the position to 12,628 shares worth $1.18M. The position accounts for 0.24% of the portfolio, ranked #32.

Paul John Balson first reported a position in ARKG in Q2 2020 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold ARKG as of Q4 2020.

Paul John Balson held 12,628 shares of ARK Genomic Revolution ETF worth $1.18M as of Q4 2020.
Paul John Balson bought 4,308 ARK Genomic Revolution ETF shares in Q4 2020, an estimated $343K.
ARK Genomic Revolution ETF made up 0.24% of Paul John Balson's portfolio in Q4 2020, its #32 holding.
Paul John Balson first reported a position in ARK Genomic Revolution ETF in Q2 2020 and has held it in 3 quarters since.
414 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2020.

Based on Paul John Balson's 13F filing for Q4 2020, filed 17 Feb 2021.